CSIMarket
 
Adicet Bio Inc   (NASDAQ: ACET)
Other Ticker:  
 
 
Price: $0.9652 $-0.06 -6.291%
Day's High: $1.06 Week Perf: 7.54 %
Day's Low: $ 0.96 30 Day Perf: -1.71 %
Volume (M): 1,325 52 Wk High: $ 3.47
Volume (M$): $ 1,279 52 Wk Avg: $1.50
Open: $1.06 52 Wk Low: $0.81



 Market Capitalization (Millions $) 88
 Shares Outstanding (Millions) 91
 Employees 66
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -118
 Cash Flow (TTM) (Millions $) -78
 Capital Exp. (TTM) (Millions $) 1

Adicet Bio Inc
Adicet Bio Inc is a clinical-stage biotechnology company that is at the forefront of developing cutting-edge therapies for cancer patients. The company was founded in 2015 and is headquartered in Menlo Park, California, with additional locations in Texas and Israel. Adicet Bio is a privately held company and has raised over $253 million in venture capital funding.

Adicet Bio is focused on developing novel immunotherapies that harness the power of the immune system to treat various forms of cancer. The company's platform technology uses ee T cells as a delivery vehicle for chimeric antigen receptor (CAR) and T cell receptor (TCR) therapies, enabling the cells to recognize and destroy cancer cells. The company's proprietary technology platform is based on over 20 years of research in the field of ee T cells.

Adicet Bio has a pipeline of several promising therapies in various stages of development, including ADI-001, which is being developed for the treatment of solid tumors. The drug is designed to target the B7-H3 antigen, which is overexpressed on several types of cancer cells, including breast, ovarian, bladder, and lung cancers. The therapy is currently in Phase 1 clinical trials.

Another promising therapy in Adicet Bio's pipeline is ADI-101, which is being developed for the treatment of non-Hodgkin's lymphoma (NHL). The drug incorporates the company's ee T cell platform technology and is designed to target the CD20 antigen, which is present on the surface of B cells. The therapy is currently in preclinical development.

Adicet Bio has a strong team of experienced executives and scientists who are dedicated to advancing innovative cancer therapies. The company is led by CEO Anil Singhal, who has over 20 years of experience in the biotechnology industry. The company's scientific team is led by Dr. Aya Jakobovits, who has a Ph.D. in Immunology from the Weizmann Institute of Science and has over 25 years of experience in the biotechnology industry.

In summary, Adicet Bio Inc is a clinical-stage biotechnology company that uses ee T cells as a delivery vehicle for innovative immunotherapies to treat cancer patients. The company has a strong pipeline of promising therapies in various stages of development and a dedicated team of experienced executives and scientists.


   Company Address: 131 Dartmouth Street Boston 2116 MA
   Company Phone Number: 503-9095   Stock Exchange / Ticker: NASDAQ ACET


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
BMY   -5.17%    
KPTI        1.43% 
MEIP        0.54% 
RYTM   -0.39%    
SUPN        2.78% 
YMAB        3.97% 
• View Complete Report
   



Business Update

Adicet Bio Marks Key Advances in Cancer Treatment with Success in Phase 1 Trials for ADI-270 and Promising Biomarke...

Published Thu, Dec 19 2024 1:47 PM UTC

Adicet Bio, Inc., a pioneering biotechnology firm focused on the development of allogeneic gamma delta T cell therapies, has made significant strides in the fight against cancer and autoimmune diseases with the recent initiation of two groundbreaking clinical initiatives. With excitement building in the immunotherapy landscape, the company has announced the dosing of its fir...

Business Update

Adicet Bios ADI-270 Enrollment Launch A Promising Step in the Fight Against Advanced Renal Cell Carcinoma,

Published Tue, Nov 19 2024 5:10 AM UTC

In the ever-evolving landscape of oncology, the race to find effective treatments for solid tumors remains an urgent challenge, particularly for metastatic and advanced clear cell renal cell carcinoma (ccRCC). Amidst this daunting backdrop, Adicet Bio, Inc., a pioneering clinical stage biotechnology company, has bolstered its commitment to addressing this critical unmet medi...

Business Update

ADI-001 A Promising Off-the-Shelf CAR T Cell Therapy Augmenting Treatment for Autoimmune Diseases

Published Mon, Nov 18 2024 7:15 AM UTC

Adicet Bio, Inc., a clinical-stage biotechnology firm, is making strides in the field of allogeneic, gamma delta T cell therapies aimed at treating autoimmune diseases and cancer. In recent developments, the company presented significant clinical biomarker data at the American College of Rheumatology (ACR) Convergence 2024, which highlights the potential impact of their nov...

Business Update

Adicet Bio Presents Clinical Biomarker Data on Off-the-Shelf CAR T Cell Therapy at ACR Convergence 2024, Demonstrat...

Published Sat, Nov 16 2024 4:50 PM UTC

Adicet Bio Unveils Promising Clinical Biomarker Data for Off-the-Shelf CAR T Cell Therapy at ACR Convergence 2024 In a landmark moment for the field of immunotherapy, Adicet Bio, Inc. (Nasdaq: ACET), a clinical-stage biotechnology company specialized in developing allogeneic gamma delta T cell therapies, announced the presentation of significant clinical biomarker data from ...

Business Update

Adicet Bio Announces FDA Clearance of IND Amendment to Evaluate ADI-001 in Idiopathic Inflammatory Myopathy and Stiff...

Published Wed, Oct 16 2024 12:12 PM UTC

Adicet Bio Secures FDA Approval for Pioneering Trials of ADI-001 in Rare Autoimmune Disorders: Idiopathic Inflammatory Myopathy and Stiff Person Syndrome to ADI-001 and Its Potential Impact In an exciting development for the treatment of rare autoimmune disorders, Adicet Bio, Inc., a leading clinical-stage biotechnology firm, has successfully secured approval from the Unit...










Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com